Retinalamin

Release form:

lyophilisate for prigot. solution for d / v / m and parabulbar injection of 5 mg / vial. 10 pieces.

Description Retinalamin:

Lyophilisate for preparation of a solution for intramuscular injection and parabulbar administration in the form of a powder or a porous mass of white or white with a yellowish tinge.

complex of water-soluble polypeptide fractions of the cattle retina (retinalamin) 5 mg
Excipients : glycine - 17 mg (stabilizer).
22 mg - vials of colorless glass with a capacity of 5 ml

Pharmachologic effect Retinalamin:

A drug that improves the regeneration of retinal tissues for systemic use in ophthalmology
Other drugs for the treatment of eye diseases. (Glaucoma, Retinopathy, Injury to the eye and orbit)
Tissue regeneration stimulant.

Active substance Retinalamin:

cattle retinal polypeptides

Pharmaco-therapeutic group Retinalamin:

Tissue repair stimulant

pharmachologic effect Retinalamin:

Complex of water-soluble polypeptide fractions of the cattle retina. It has a stimulating effect on the photoreceptors and cellular elements of the retina, improves the functional interaction of the pigment epithelium and the outer segments of photoreceptors, glial cells in case of degenerative changes, accelerates the restoration of light sensitivity of the retina. Normalizes vascular permeability, reduces manifestations of local inflammatory reactions, stimulates reparative processes in diseases and injuries of the retina.

The mechanism of action is determined by the metabolic activity of the agent: it improves the metabolism of eye tissues and normalizes the functions of cell membranes, improves intracellular protein synthesis, regulates lipid peroxidation processes, and helps to optimize energy processes.

Indications Retinalamin:

• Compensated primary open-angle glaucoma
• diabetic retinopathy
• central retinal dystrophy of inflammatory and traumatic genesis
• central retinal dystrophy
• myopic disease (as part of complex therapy)
• central and peripheral tapetoretinal abiotrophy
• rhematogenous and traumatic retinal detachment (as part of the rehabilitation postoperative period).
• Retinal detachment with retinal tear
• Degeneration of the macula and posterior pole
• Hereditary retinal dystrophies
• Other specified retinal disorders
• Diabetic retinopathy
• Primary open-angle glaucoma
• Myopia, Glaucoma, Retinopathy, Injury to the eye and orbit

How to take, course and dosage Retinalamin:

Apply parabulbarly. The dose, scheme and duration of therapy are set individually, depending on the indications and age of the patient.

Drug interactions Retinalamin:

The product is not recommended to be mixed with other solutions.

Application during pregnancy and lactation Retinalamin:

The drug is contraindicated for use during pregnancy (no data on efficacy and safety).
If necessary, the appointment of the drug during lactation, breastfeeding should be discontinued.

Side effect Retinalamin:

From the immune system: anaphylactic shock, angioedema of the larynx.
Local reactions: pain, hyperemia and edema at the injection site.

Contraindications Retinalamin:

Hypersensitivity to the components of the product; age up to 18 years (with compensated primary open-angle glaucoma, diabetic retinopathy, myopic disease, rhegmatogenous and traumatic retinal detachment - due to the lack of data on efficacy and safety); age up to 1 year (with central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy).

Special instructions Retinalamin:

If the injection is missed, it is not recommended to enter a double dose, but to carry out the next injection as usual on the scheduled day.

Influence on the ability to drive vehicles and mechanisms
Care should be taken when driving vehicles mechanisms
because in the case of parabulbar injections of this agent and concomitant examination of vision
temporary visual impairments are possible that affect the performance of potentially hazardous activities that require special attention and quick reactions (driving, working with moving mechanisms).

Application in children Retinalamin:

The drug is contraindicated for use in children under the age of 18 with compensated primary open-angle glaucoma, diabetic retinopathy, myopic disease, rhematogenous and traumatic retinal detachment (due to the lack of data on efficacy and safety); in children under the age of 1 year with central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy.